Keros Therapeutics Inc Ownership
$11.36
5.77%
Nasdaq, Sep 17, 04:10 pm EDT.
Closed.
Keros Therapeutics Inc Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
BlackRock Institutional Trust Company, N.A.
|
1.998m | 10.08% | +85.893k | Mar 31 2026 |
| 2 |
Nantahala Capital Management, LLC
|
1.360m | 6.86% | +1.000m | Mar 31 2026 |
| 3 |
Vanguard Capital Management, LLC
|
831.421k | 4.19% | +831.421k | Mar 31 2026 |
| 4 |
OrbiMed Advisors, LLC
|
759.155k | 3.83% | -45.057k | Mar 31 2026 |
| 5 |
Qube Research & Technologies Ltd
|
724.926k | 3.66% | -58.992k | Mar 31 2026 |
|
1
BlackRock Institutional Trust Company, N.A.
|
10.08%
1.998m
|
|
2
Nantahala Capital Management, LLC
|
6.86%
1.360m
|
|
3
Vanguard Capital Management, LLC
|
4.19%
831.421k
|
|
4
OrbiMed Advisors, LLC
|
3.83%
759.155k
|
|
5
Qube Research & Technologies Ltd
|
3.66%
724.926k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 28.61% of Keros Therapeutics Inc, with BlackRock Institutional Trust Company, N.A. the biggest at 10.08%, followed by Nantahala Capital Management, LLC (6.86%) and Vanguard Capital Management, LLC (4.19%). |
Recent Keros Therapeutics Inc Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Sep 18 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 15 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 11 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 06 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Aug 31 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Aug 24 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Sep 18 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 15 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 11 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 06 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Aug 31 2026
$170.50
|
|
Lisa Park
SALES
|
Aug 24 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Keros Therapeutics Inc Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Keros Therapeutics Inc has fallen over the past 12 months from around 17.4% to 6.8% of the float. Fewer and fewer market participants are betting on falling prices. That points to easing skepticism, as short sellers increasingly unwind their positions. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
